Sebastian Łabuda

Sebastian Łabuda

Auto-generated profile, based on publicly available information

Sebastian Łabuda

Department of Psychiatry, St. Jadwiga Regional Specialised Hospital, Opole, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Behavioural Neurology
Verified
Journal Article
Open access
ASAlicja Sierakowska
Alicja Sierakowska
ENEwa Niewiadomska
Ewa Niewiadomska
SŁSebastian Łabuda
Sebastian Łabuda
ABAnna Bieniasiewicz
Anna Bieniasiewicz
MRMateusz Roszak
Mateusz Roszak
BŁBeata Łabuz-Roszak
Beata Łabuz-Roszak
Schizophrenia (SZ) is categorized as a chronic severe highly heritable brain disease. Symptoms include positive, negative, and cognitive symptoms. Despite numerous theories concerning the etiopathogenesis of SZ, the symptoms, although characteristic in their phenomenology, manifest themselves in a rather heterogeneous manner, which makes them subject to clinical assessment and, at the same time, prone to errors resulting from diverse interpretations of the context of the patient′s statements. Therefore, current research is focusing on identifying more subtle and stable features of SZ, such as the phenotype, endophenotype, and assessable abnormalities devoid of human clinical observation. The various biomarker developments focus on the role of transmitters and their corresponding receptors, in particular: glutamate, acetylcholine, dopamine, or serotonin. Also important in terms of etiopathogenesis remain growth factors such as brain‐derived neurotrophic factor (BDNF), nerve growth factor receptor (NGFR), or vascular endothelial growth factor (VEGF). More recently, research has emphasized the role of inflammatory processes and secreted pro‐ as well as anti‐inflammatory cytokines, included in the class of interleukins, chemokines, and tumor necrosis factors, as well as on inflammatory markers—C‐reactive protein (CRP) or glutathione (GSH). Increasingly, changes at the genetic level have been implicated as the cause of diseases, and it is now believed that noncoding RNAs (micro‐RNA [miRNA], long noncoding RNA [lnc‐RNA], and circular RNA [circRNA]) are involved in the development of SZ. Among the genes that may prove to be potential biomarkers in SZ belong SEDT1A, FOXP2, GRIN2A, GRIA3, NRN1, BDNF, CACNA1C, and ZNF8A4. The peptide group molecules, Phospholipase A2, Klotho protein, and soluble urokinase plasminogen activator receptor (suPAR), also remain consistently important. From the perspective of SZ as a disease associated with neuronal damage, biomarkers correlating with brain injury, neuron‐specific enolase (NSE), and S100B protein should be considered.

29 August 2025 in Aktualności Neurologiczne
Verified
Journal Article
Open access
PDF file
ASAlicja Sierakowska
Alicja Sierakowska
ENEwa Niewiadomska
Ewa Niewiadomska
SŁSebastian Łabuda
Sebastian Łabuda
ABAnna Bieniasiewicz
Anna Bieniasiewicz
MRMateusz Roszak
Mateusz Roszak
BŁBeata Łabuz-Roszak
Beata Łabuz-Roszak
Introduction: Early diagnosis of ischaemic stroke and prompt implementation of causal treatment can improve patient outcomes. Recently, special attention has been paid to biomarkers associated with neuronal damage. One of them is neuron-specific enolase (NSE). Studies conducted to date indicate an increase in NSE concentration in patients with acute ischaemic stroke. The aim of this study was to assess serum NSE concentrations in patients with acute ischaemic stroke, and to determine the possible relationship between NSE levels and clinical features of the disease. Materials and methods: This case-control study included 60 patients with acute ischaemic stroke and 60 healthy controls (Opole, Poland, 2023). Demographic and clinical data were collected in the study group, and laboratory tests were performed. NSE concentrations in blood serum were determined in both groups. Results: No statistically significant differences were observed in the mean NSE concentrations between the study and control groups. However, above-normal NSE values were observed significantly more frequently in patients with ischaemic stroke. Significant differences in NSE levels were noted depending on the type of stroke (highest for partial anterior circulation infarct, PACI), stroke aetiology (highest for atherogenic stroke), and the level of disability (highest in completely dependent patients). Above-normal NSE values were also significantly associated with a longer time since the occurrence of ischaemic stroke. Conclusions: The type and aetiology of stroke, time from the first symptoms and degree of dependence influenced the serum concentration of NSE in stroke patients. Further research in this area is warranted.